Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
NCT02247583
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study
- Patients who are not able to understand Dutch or French will be excluded from the
study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- São Paulo,
- Leuven,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment | |||
Official Title | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug. | |||
Brief Summary | Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug. The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug. The following aspects will be investigated:
This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period. | |||
Detailed Description | Not Provided | |||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | mRCC patients starting with an oral anti-cancer treatment | |||
Condition | Clear Cell Renal Cell Carcinoma | |||
Intervention | Not Provided | |||
Study Groups/Cohorts | mRCC patients
Patients with metastatic renal cell carcinoma | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 90 | |||
Original Actual Enrollment | Same as current | |||
Actual Study Completion Date | July 2013 | |||
Actual Primary Completion Date | July 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Belgium | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT02247583 | |||
Other Study ID Numbers | VF/2010/03 s52586 ( Registry Identifier: Clinical Trial Center UZ Leuven ) | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Sandra De Coster, KU Leuven | |||
Study Sponsor | KU Leuven | |||
Collaborators |
| |||
Investigators |
| |||
PRS Account | KU Leuven | |||
Verification Date | September 2014 |